<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00724360</url>
  </required_header>
  <id_info>
    <org_study_id>BRD04/2-T</org_study_id>
    <nct_id>NCT00724360</nct_id>
  </id_info>
  <brief_title>Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)</brief_title>
  <official_title>A Phase II Trial Evaluating the Safety and the Efficacy of Trastuzumab in Relapsed/Refractory HER2 Positive B-acute Lymphoblastic Leukemia Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <brief_summary>
    <textblock>
      This is a multicenter open-label phase II trial of trastuzumab in patients with HER2 positive
      B-ALL in relapse, or with refractory disease. Herceptin is administered as a 4 mg/kg
      intravenous loading dose followed by 2 mg/kg weekly for at least 2 months and/or till
      progression. Response and HER2 expression are assessed each month by bone marrow aspirate.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulties of recruitment
  </why_stopped>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate: Response was defined either as complete response (CR), CR without recovery of platelet (CRp), or partial response (PR)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trastuzumab efficiency concerning transfusional needs</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cytogenetic response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trastuzumab tolerance profile</measure>
  </secondary_outcome>
  <enrollment type="Actual">15</enrollment>
  <condition>Relapsed/Refractory Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin (trastuzumab)</intervention_name>
    <description>Administered as a 4 mg/kg intravenous loading dose followed by 2 mg/kg weekly for at least 2 months and/or until progression</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  B-ALL in relapse

          -  refractory B-ALL-performance status of 0-2 on the Eastern Cooperative Oncology Group
             scale

          -  adequate hepatic and renal functions (AST or ALT &lt;= 5 times the upper limit of normal
             creatinine &lt; 2 times the upper limit of normal)

          -  &gt; 20% blasts in bone marrow,

          -  &gt; 30% of bone marrow blast population HER2 positive as assessed by immunophenotyping

        Exclusion Criteria:

          -  Previous treatment by trastuzumab

          -  FEVG &lt; 50%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clermont-Ferrand University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mondor Hospital</name>
      <address>
        <city>Cr√©teil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grenoble Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strasbourg University Hospital</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2008</study_first_submitted>
  <study_first_submitted_qc>July 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2008</study_first_posted>
  <last_update_submitted>October 4, 2013</last_update_submitted>
  <last_update_submitted_qc>October 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsed/refractory</keyword>
  <keyword>HER2</keyword>
  <keyword>positive</keyword>
  <keyword>B-ALL</keyword>
  <keyword>trastuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

